[{"orgOrder":0,"company":"MEDUNIK CANADA","sponsor":"Jacobus Pharmaceutical Company, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","graph1":"Immunology","graph2":"Approved","graph3":"MEDUNIK CANADA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MEDUNIK CANADA \/ Jacobus Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"MEDUNIK CANADA \/ Jacobus Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by MEDUNIK CANADA

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Médunik Canada has retained the services of Innomar, a leading specialty pharmaceutical service and patient support program provider, for the distribution of Ruzurgi® and management of its UnikAccess Patient Support Program.

                          Brand Name : Ruzurgi

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 25, 2020

                          Lead Product(s) : Amifampridine Phosphate

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Jacobus Pharmaceutical Company, Inc

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank